CD79B and MYD88 mutations in diffuse large B-cell lymphoma

Human Pathology

Volumn 45, Issue 3, 2014, Pages 556-564

  Kim, Yuil ^a   Ju, Hyunjeong ^b   Kim, Dong Hoon ^c   Yoo, Hae Yong ^a   Kim, Suk Jin ^a   Kim, Won Seog ^a   Ko, Young Hyeh ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Hallym University   (South Korea)

Author keywords

CD79B; Diffuse large B cell lymphoma; Mutation; MYD88

Indexed keywords

CD79B; DIFFUSE LARGE B CELL LYMPHOMA; MUTATION; MYD88;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, CD79; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; PROGNOSIS;

EID: 84894044912     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2013.10.023     Document Type: Article

References (29)

1. N.D. Perkins The diverse and complex roles of NF-kappaB subunits in cancer Nat Rev Cancer 12 2012 121 132
2. K.H. Lim, Y. Yang, and L.M. Staudt Pathogenetic importance and therapeutic implications of NF-kappaB in lymphoid malignancies Immunol Rev 246 2012 359 378
3. A.A. Alizadeh, M.B. Eisen, and R.E. Davis et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 2000 503 511
4. A.S. Baldwin Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB J Clin Invest 107 2001 241 246
5. G. Lenz, G. Wright, and S.S. Dave et al. Stromal gene signatures in large-B-cell lymphomas N Engl J Med 359 2008 2313 2323
6. R.E. Davis, V.N. Ngo, and G. Lenz et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 463 2010 88 92
7. T. Kawai, and S. Akira The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Nat Immunol 11 2010 373 384
8. V.N. Ngo, R.M. Young, and R. Schmitz et al. Oncogenically active MYD88 mutations in human lymphoma Nature 470 2011 115 119
9. S.P. Treon, L. Xu, and G. Yang et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia N Engl J Med 367 2012 826 833
10. M. Varettoni, L. Arcaini, and S. Zibellini et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms Blood 121 2013 2522 2528
11. L. Xu, Z.R. Hunter, and G. Yang et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction Blood 121 2013 2051 2058
12. J.J. Steinhardt, and R.B. Gartenhaus Promising personalized therapeutic options for diffuse large B-cell lymphoma subtypes with oncogene addictions Clin Cancer Res 18 2012 4538 4548
13. S.H. Swerdlow, E. Campo, and N.L. Harris et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008 International Agency for Research on Cancer Lyon
14. C.P. Hans, D.D. Weisenburger, and T.C. Greiner et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 103 2004 275 282
15. S. Park, J. Lee, and Y.H. Ko et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma Blood 110 2007 972 978
16. L.S. Young, and A.B. Rickinson Epstein-Barr virus: 40 years on Nat Rev Cancer 4 2004 757 768
17. L.H. Sehn Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma Hematol Am Soc Hematol Educ Program 2012 2012 402 409
18. A. Lopez-Guillermo, L. Colomo, and M. Jimenez et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin J Clin Oncol 23 2005 2797 2804
19. J.G. Lohr, P. Stojanov, and M.S. Lawrence et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing Proc Natl Acad Sci U S A 109 2012 3879 3884
20. L. Pasqualucci, V. Trifonov, and G. Fabbri et al. Analysis of the coding genome of diffuse large B-cell lymphoma Nat Genet 43 2011 830 837
21. R.D. Morin, M. Mendez-Lago, and A.J. Mungall et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma Nature 476 2011 298 303
22. W.W. Choi, D.D. Weisenburger, and T.C. Greiner et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy Clin Cancer Res 15 2009 5494 5502
23. A. Gonzalez-Aguilar, A. Idbaih, and B. Boisselier et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas Clin Cancer Res 18 2012 5203 5211
24. A. Pham-Ledard, D. Cappellen, F. Martinez, B. Vergier, M. Beylot-Barry, and J.P. Merlio MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type J Invest Dermatol 132 2012 2118 2120
25. J.W. Choi, Y. Kim, J.H. Lee, and Y.S. Kim MYD88 expression and L265P mutation in diffuse large B-cell lymphoma Hum Pathol 44 2013 1375 1381
26. W. Klapper, M. Kreuz, and C.W. Kohler et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma Blood 119 2012 1882 1887
27. S. Poulain, C. Roumier, and A. Decambron et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia Blood 121 2013 4504 4511
28. C. Jimenez, E. Sebastian, and M.C. Chillon et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia Leukemia 27 2013 1722 1728
29. T.L. Naylor, H. Tang, and B.A. Ratsch et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas Cancer Res 71 2011 2643 2653